Long Noncoding RNAs in Atherosclerosis

Zhang, Zhengyi; Salisbury, David; Sallam, Tamer

doi:10.1016/j.jacc.2018.08.2161

Cited by 90 publications

(58 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inflammation is involved in the pathogenesis of atherosclerosis as well as its complications, and therefore anti-inflammatory therapies have recently been proposed to improve the prognosis of individuals with atherosclerosis [3] . Accumulating evidence reveals the role of long noncoding RNAs (lncRNAs) in controlling atherosclerosis and inflammation-related diseases, thus highlighting them as important therapeutic targets [4] , [5] .…”

Section: Introductionmentioning

confidence: 99%

Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulation

Xing

Zhang

et al. 2020

Journal of Advanced Research

View full text Add to dashboard Cite

Graphical abstract The map illustrating mechanisms associated with lncRNA HIF1A-AS2-mediated inflammation in the atherosclerosis. LncRNA HIF1A-AS2 forms a complex with USF1, which is recruited into the ATF2 promoter to elevate ATF2 expression, thus promoting the development of atherosclerotic inflammation. Meanwhile, downregulation of lncRNA HIF1A-AS2 decreases the expression of ATF2 by reducing the binding of USF1 to the ATF2 promoter regions, thereby inhibiting atherosclerotic inflammation, as reflected by decreased inflammatory factors TNF-α, IL-1β and IL-6 in serum and protein levels of adhesion molecules VCAM-1, ICAM-1, and MCP-1, as well as increased cell viability and reduced apoptosis in ox-LDL-induced inflammation in ECs, SMCs, and HCAECs.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulation

Xing

Zhang

et al. 2020

Journal of Advanced Research

View full text Add to dashboard Cite

show abstract

“…LncRNAs play important regulatory roles in various diseases, such as cancers, (12)(13)(14)(15) atherosclerosis, (15) neurodegeneration, (11) autoimmune disorders, (16)(17)(18)(19)(20) and chronic vascular disease. (21) Data from both in vitro hyperglycemia induction and in vivo diabetes mellitus experiments have shown that lncRNA MALAT1 is highly expressed, and that inhibition of its expression can effectively improve endothelial cell inflammation and diabetic retinopathy.…”

Section: Introductionmentioning

confidence: 99%

Analysis of long non-coding RNA expression profiles in vascular endothelial cells with hyperglycemia-induced damage

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Diabetes mellitus is often associated with microvascular and macrovascular lesions, and hyperglycemia-induced vascular endothelial cell damage is a key factor. Methods ： We investigated long non-coding RNAs (lncRNAs) and mRNAs that are affected by hyperglycemia-induced damage using human umbilical vein endothelial cells (HUVECs) as a model. HUVECs were cultured under high (25 mmol/L) or normal (5 mmol/L) glucose conditions for 6 d, and then lncRNAs and protein-coding transcripts were profiled by RNA-seq. Results ： Among 40,379 lncRNAs screened, 214 were upregulated (log2 [fold-change] > 1, FDR < 0.05) and 197 were downregulated (log2 [fold-change] < −1, FDR < 0.05) in response to high-glucose. Furthermore, among 28,431 protein-coding genes screened, 778 were upregulated and 998 were downregulated. A total of 945 lncRNA/mRNA pairs were identified, including 126 differentially expressed lncRNAs predicted to target 201 mRNAs, among which 26 were cis-regulatory interactions. The corresponding lncRNA-mRNA network was composed of 354 lncRNA nodes, 1,167 mRNA nodes and 9,735 edges. Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage, including ENST00000600527, NONHSAT037576.2, NONHSAT135706.2, ENST00000602127, NONHSAT200243.1, NONHSAT217282.1, NONHSAT176260.1, NONHSAT199075.1, NONHSAT067063.2, NONHSAT058417.2. Conclusion ： These observations may provide novel insights into the regulatory molecules and pathways of hyperglycemia-related endothelial dysfunction in diabetes-associated vascular disease.

show abstract

“…LncRNAs play important regulatory roles in various diseases, such as cancers, [12][13][14][15] atherosclerosis, [15] neurodegeneration, [11] autoimmune disorders, [16][17][18][19][20] and chronic vascular disease. [21] Data from both in vitro hyperglycemia induction and in vivo diabetes mellitus experiments have shown that lncRNA MALAT1 is highly expressed, and that inhibition of its expression can effectively improve endothelial cell in ammation and diabetic retinopathy.…”

Section: Introductionmentioning

confidence: 99%

Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Diabetes mellitus is often associated with microvascular and macrovascular lesions, and hyperglycemia-induced vascular endothelial cell damage is a key factor. Methods： We investigated long non-coding RNAs (lncRNAs) and mRNAs that are affected by hyperglycemia-induced damage using human umbilical vein endothelial cells (HUVECs) as a model. HUVECs were cultured under high (25 mmol/L)or normal normal (5 mmol/L) glucose conditions for 6 d, and then lncRNAs and protein-coding transcripts were profiled by RNA-seq. Results： Among 40,379 lncRNAs screened, 214 were upregulated (log2 [fold-change] > 1, FDR < 0.05) and 197 were downregulated (log2 [fold-change] < −1, FDR < 0.05) in response to high-glucose. Furthermore, among 28,431 protein-coding genes screened, 778 were upregulated and 998 were downregulated. A total of 945 lncRNA/mRNA pairs were identified, including 126 differentially expressed lncRNAs predicted to target 201 mRNAs, among which 26 were cis-regulatory interactions. The corresponding lncRNA-mRNA network was composed of 354 lncRNA nodes, 1,167 mRNA nodes and 9,735 edges. Dozens of lncRNAs with high degree may play important roles in high-glucose-induced HUVEC damage, including ENST00000600527, NONHSAT037576.2, NONHSAT135706.2, ENST00000602127, NONHSAT200243.1, NONHSAT217282.1, NONHSAT176260.1, NONHSAT199075.1, NONHSAT067063.2, NONHSAT058417.2. Conclusion： These observations may provide novel insights into the regulatory molecules and pathways of hyperglycemia-related endothelial dysfunction in diabetes-associated vascular disease.

show abstract

Long Noncoding RNAs in Atherosclerosis

Cited by 90 publications

References 67 publications

Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulation

Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulation

Analysis of long non-coding RNA expression profiles in vascular endothelial cells with hyperglycemia-induced damage

Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells

Contact Info

Product

Resources

About